{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": -0.34723017, "regularMarketPrice": 5.74, "earningsTimestamp": 1684153800, "earningsTimestampStart": 1684153800, "earningsTimestampEnd": 1684153800, "trailingAnnualDividendRate": 0.0, "trailingPE": 7.1749997, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 0.8, "epsForward": -1.42, "epsCurrentYear": -4.19, "priceEpsCurrentYear": -1.3699284, "sharesOutstanding": 20947800, "bookValue": 2.216, "fiftyDayAverage": 4.15258, "fiftyDayAverageChange": 1.58742, "fiftyDayAverageChangePercent": 0.3822732, "twoHundredDayAverage": 2.9966724, "twoHundredDayAverageChange": 2.7433274, "twoHundredDayAverageChangePercent": 0.9154579, "marketCap": 120387888, "forwardPE": -4.0422535, "priceToBook": 2.5902524, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1604905200000, "priceHint": 2, "marketState": "REGULAR", "exchange": "FRA", "shortName": "OCUPHIRE PHARMA DL-,0001", "longName": "Ocuphire Pharma, Inc.", "messageBoardId": "finmb_560534013", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChange": -0.020000458, "regularMarketTime": 1683903602, "regularMarketDayHigh": 5.8, "regularMarketDayRange": "5.74 - 5.8", "regularMarketDayLow": 5.74, "regularMarketVolume": 333, "regularMarketPreviousClose": 5.76, "bid": 5.78, "ask": 5.92, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 5.79, "averageDailyVolume3Month": 120, "averageDailyVolume10Day": 63, "fiftyTwoWeekLowChange": 4.0629997, "fiftyTwoWeekLowChangePercent": 2.4227786, "fiftyTwoWeekRange": "1.677 - 6.01", "fiftyTwoWeekHighChange": -0.27000046, "fiftyTwoWeekHighChangePercent": -0.044925198, "fiftyTwoWeekLow": 1.677, "fiftyTwoWeekHigh": 6.01, "symbol": "R3X1.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "37000 Grand River Avenue", "address2": "Suite 120", "city": "Farmington Hills", "state": "MI", "zip": "48335", "country": "United States", "phone": "248 681 9815", "website": "https://www.ocuphire.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard J. Rodgers M.B.A.", "age": 55, "title": "Interim CEO, Interim Pres & Director", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 62000, "fmt": "62k", "longFmt": "62,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Mina Patel Sooch M.B.A., MBA", "age": 54, "title": "Founder, Treasurer & Director", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 882590, "fmt": "882.59k", "longFmt": "882,590"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 445239, "fmt": "445.24k", "longFmt": "445,239"}}, {"maxAge": 1, "name": "Ms. Amy  Zaremba Rabourn C.P.A., CPA, MAcc", "age": 41, "title": "Sr. VP of Fin.", "yearBorn": 1981, "fiscalYear": 2022, "totalPay": {"raw": 384516, "fmt": "384.52k", "longFmt": "384,516"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 39724, "fmt": "39.72k", "longFmt": "39,724"}}, {"maxAge": 1, "name": "Mr. Bernhard  Hoffmann M.B.A.", "age": 66, "title": "Sr. VP of Corp. Devel. & Operations and Sec.", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": {"raw": 348958, "fmt": "348.96k", "longFmt": "348,958"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 190540, "fmt": "190.54k", "longFmt": "190,540"}}, {"maxAge": 1, "name": "Dr. Daniela C. Oniciu Ph.D.", "title": "Global Head of R&D, Chemistry and Product Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mitchell  Brigell Ph.D.", "title": "Head of Clinical Devel. & Strategy", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chris  Ernst", "title": "Global Head of QA & Manufacturing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Bindu  Manne", "title": "Head of Market Devel. & Commercialization", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Erik  Sims", "title": "Director & Corp. Controller", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ronil A Patel M.S.", "title": "VP of Bus. Devel. & Market Strategy", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}